It was also reported that, following the administration of sirolimus, there was a reduction of the tumor burden in LHBETATAG transgenic retinoblastoma tumors [Murray TG, Piña Y, Houston S, et al. Retinoblastoma Tumor Burden Control: Periocular mTOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma. This evidence concerns the gene MTOR and retinoblastoma.